Monday, March 15, 2010 Last update: 3:30 AM

State-by-State AND City-by-City FreshNews.com Delivers Company Tech News

Cell Therapeutics, Inc.

print this company - email to a friend - join our eNewsletter

News articles for Cell Therapeutics, Inc.:

Sunday, March 7, 2010

FDA Approves NerPharMa to Manufacture Cell Therapeutics' Drug Pixantrone

Posted at 03/08/2010 - 12:30am

Wednesday, March 3, 2010

Gynecologic Oncology Group (GOG) Notifies CTI That Continuation of GOG-212 Pivotal Trial of OPAXIO Maintenance Therapy in Front Line Ovarian Cancer Remains High Priority

Posted at 03/04/2010 - 12:30am

Monday, March 1, 2010

FDA Sets March 22 for ODAC Meeting to Review CTI's New Drug Application for Pixantrone

Posted at 03/01/2010 - 11:02am

Friday, February 26, 2010

Cell Therapeutics Announces Filing of Form 10-K

Posted at 02/26/2010 - 3:40pm

Wednesday, February 10, 2010

Cell Therapeutics, Inc. (CTI) Decreases Net Loss by 42% in 2009

Posted at 02/11/2010 - 12:30am

Monday, February 8, 2010

FDA Postpones Oncologic Drugs Advisory Committee Meeting to Review Pixantrone Due to Severe Weather Conditions

Posted at 02/09/2010 - 12:30am

Sunday, February 7, 2010

Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2009 Financial Results on February 11

Posted at 02/08/2010 - 12:30am

Wednesday, January 13, 2010

Cell Therapeutics, Inc. Announces Institutional Investors Purchase $30 Million of Preferred Stock and Warrants

Posted at 01/13/2010 - 5:03pm

Sunday, January 10, 2010

Cell Therapeutics, Inc. (CTI) to Present at the 28th Annual JP Morgan Healthcare Conference

Posted at 01/11/2010 - 12:30am

Sunday, December 27, 2009

Cell Therapeutics, Inc. Adopts Shareholder Rights Plan

Posted at 12/28/2009 - 12:30am

Monday, December 21, 2009

Cell Therapeutics Commits to PhRMA's Code on Interactions With Healthcare Professionals

Posted at 12/22/2009 - 12:30am

Sunday, December 20, 2009

European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)

Posted at 12/21/2009 - 12:30am

Wednesday, December 16, 2009

Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010

Posted at 12/17/2009 - 12:45am

Monday, December 7, 2009

Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines

Posted at 12/08/2009 - 12:30am

Sunday, December 6, 2009

Pixantrone Produces 250% Relative Improvement in 1 Year Progression Free Survival for Patients With Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma Across All Measured Risk Factors - Updated Fo

Posted at 12/07/2009 - 12:30am

Monday, November 30, 2009

Cell Therapeutics, Inc. (CTI) Piper Jaffray Presentation to be Webcast

Posted at 12/01/2009 - 12:30am

Sunday, November 29, 2009

New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents

Posted at 11/30/2009 - 12:30am

Monday, November 23, 2009

Cell Therapeutics, Inc. (CTI) to Present at 21st Annual Piper Jaffray Health Care Conference

Posted at 11/24/2009 - 12:30am

Friday, November 20, 2009

Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group

Posted at 11/20/2009 - 2:30am

Wednesday, November 4, 2009

Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45%

Posted at 11/05/2009 - 12:30am

Add new comment

Biotech/Biomedical/Health

California

Florida

Louisiana

Pennsylvania

Washington

United States